Introduction of Hib conjugate vaccines in the non-industrialized world: experience in four 'newly adopting' countries.
Hib conjugate vaccines are widely used in the industrialized world, but are just now beginning to be introduced into other countries. To identify factors facilitating rapid global introduction, we evaluated the decision-making process, mode of introduction, effectiveness, and impact on the immunization program of Hib conjugate vaccine introduction in four non- industrialized countries through site visits and use of a standardized questionnaire. The key promoters of Hib introduction were the pediatric community and ministries of health. Local surveillance and severity data were critical in the decision to adopt Hib vaccine. Assistance with surveillance, introduction guidelines, educational material, tenders, and funding is needed to accelerate wider adoption.
Wenger
J D
JD
Childrens Vaccine Initiative, c/o World Health Organization (WHO), Geneva, Switzerland. wengerj@who.int
DiFabio
J
J
Landaverde
J M
JM
Levine
O S
OS
Gaafar
T
T
D002677:Chile; D003657:Decision Making; D003906:Developing Countries; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000008:administration & dosage; D014943:Global Health; D006192:Haemophilus Infections / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage*; D006193:Haemophilus influenzae / Q000276:immunology; D006801:Humans; D017589:Immunization Programs; D007223:Infant; D007231:Infant, Newborn; D007730:Kuwait; D011780:Qatar; D014583:Uruguay; D018074:Vaccines, Conjugate / Q000008:administration & dosage
D015721:Diphtheria-Tetanus-Pertussis Vaccine; D018073:Haemophilus Vaccines; D018074:Vaccines, Conjugate; C080881:diphtheria-tetanus-pertussis-haemophilus b conjugate vaccine